Current programmable nuclease-based methods (for example, CRISPR-Cas9) for the precise correction of a disease-causing genetic mutation harness the homology-directed repair pathway. However, this repair process requires the co-delivery of an exogenous DNA donor to recode the sequence and can be inefficient in many cell types. Here we show that disease-causing frameshift mutations that result from microduplications can be efficiently reverted to the wildtype sequence simply by generating a DNA double-stranded break near the centre of the duplication. We demonstrate this in patientderived cell lines for two diseases: limb-girdle muscular dystrophy type 2G (LGMD2G) 1 and Hermansky-Pudlak syndrome type 1 (HPS1) 2 . Clonal analysis of inducible pluripotent stem (iPS) cells from the LGMD2G cell line, which contains a mutation in TCAP, treated with the Streptococcus pyogenes Cas9 (SpCas9) nuclease revealed that about 80% contained at least one wild-type TCAP allele; this correction also restored TCAP expression in LGMD2G iPS cell-derived myotubes. SpCas9 also efficiently corrected the genotype of an HPS1 patient-derived B-lymphoblastoid cell line. Inhibition of polyADP-ribose polymerase 1 (PARP-1) suppressed the nuclease-mediated collapse of the microduplication to the wildtype sequence, confirming that precise correction is mediated by the microhomology-mediated end joining (MMEJ) pathway. Analysis of editing by SpCas9 and Lachnospiraceae bacterium ND2006 Cas12a (LbCas12a) at non-pathogenic 4-36-base-pair microduplications within the genome indicates that the correction strategy is broadly applicable to a wide range of microduplication lengths and can be initiated by a variety of nucleases. The simplicity, reliability and efficacy of this MMEJ-based therapeutic strategy should permit the development of nuclease-based gene correction therapies for a variety of diseases that are associated with microduplications.
. Clonal analysis of inducible pluripotent stem (iPS) cells from the LGMD2G cell line, which contains a mutation in TCAP, treated with the Streptococcus pyogenes Cas9 (SpCas9) nuclease revealed that about 80% contained at least one wild-type TCAP allele; this correction also restored TCAP expression in LGMD2G iPS cell-derived myotubes. SpCas9 also efficiently corrected the genotype of an HPS1 patient-derived B-lymphoblastoid cell line. Inhibition of polyADP-ribose polymerase 1 (PARP-1) suppressed the nuclease-mediated collapse of the microduplication to the wildtype sequence, confirming that precise correction is mediated by the microhomology-mediated end joining (MMEJ) pathway. Analysis of editing by SpCas9 and Lachnospiraceae bacterium ND2006 Cas12a (LbCas12a) at non-pathogenic 4-36-base-pair microduplications within the genome indicates that the correction strategy is broadly applicable to a wide range of microduplication lengths and can be initiated by a variety of nucleases. The simplicity, reliability and efficacy of this MMEJ-based therapeutic strategy should permit the development of nuclease-based gene correction therapies for a variety of diseases that are associated with microduplications.
MMEJ is an error-prone double-stranded break (DSB) DNA repair pathway that uses regions of microhomology (2-25 bp) on each side of the DSB to define the boundaries at which DNA segments are rejoined 3 . This mutagenic process generates deletions that result in the loss of one of the repeat sequences and the intervening region (Fig. 1a) . A variety of cell types show hallmarks of MMEJ repair within DNA products produced by the editing of programmable nucleases. These sequencetemplated deletion events, which produce products of a fixed length, can increase or decrease the efficiency of gene inactivation depending on the nature of the coding sequence disruption 4, 5 . The MMEJ pathway has also been harnessed for the targeted insertion of exogenous donor DNAs in mammalian cells and zebrafish and frog embryos 6, 7 . Here, we describe a nuclease-based therapeutic approach that harnesses the MMEJ pathway to precisely correct frameshift mutations resulting from microduplications (tandem duplications). We reasoned that MMEJ-based repair of a programmable nuclease-induced DSB near the centre of a disease-causing microduplication would achieve precise reversion to the wild-type genomic sequence. This strategy might be an effective alternative to homology-directed repair-based gene correction approaches and would not require co-delivery of a donor DNA. Furthermore, the reverted wild-type sequence would no longer be complementary to the single-guide RNA (sgRNA) targeting the microduplication, leading to stable correction even in the presence of Cas9 nuclease.
To evaluate the efficacy of our MMEJ-based correction strategy, we focused on LGMD2G and HPS1, two diseases that affect different human tissues and whose causes include pathogenic microduplications of different lengths. Both of these diseases are autosomal recessive disorders that are represented at modest frequencies in different human subpopulations and currently have no treatments. One of the disease alleles identified in patients with LGMD2G features an 8-bp duplication in exon 1 of TCAP, a mutation that is found in the East Asian population at a frequency of approximately 1 in 1,000 alleles. TCAP encodes the telethonin protein, a 19-kDa cardiac and striated muscle-specific structural protein located in the Z-disc of sarcomeres that links titin proteins to stabilize the contractile apparatus for muscle contraction 8 . Homozygous or compound heterozygous inactivating mutations in TCAP manifest as severe muscle atrophy and cardiomyopathy that typically develop during late adolescence into early adulthood 1, 9 . We designed and tested an sgRNA for SpCas9 to generate a DSB one base pair away from the middle of the TCAP 8-bp microduplication (Fig. 1b) . Purified SpCas9 protein was complexed with a synthetic sgRNA (RNP) and electroporated into iPS cells homozygous for the TCAP microduplication that were derived from a patient with LGMD2G. After four days, we used deep sequencing analysis to analyse the genomic region of interest for insertions and deletions (indels). We observed robust gene editing (about 80% indel rate), indicating that the SpCas9 RNP can efficiently generate DSBs at this site. Closer examination of the sequence variants revealed that on average about 57% of the alleles contained a precise 8-bp deletion corresponding to the wild-type allele (Fig. 1c, Extended Data Fig. 1a) . Notably, when introduced into wild-type cells containing functional TCAP, the SpCas9 RNPs did not cause measurable editing at the TCAP allele, indicating that the corrected allele in the mutant cells is not subject to unintended damage following MMEJ-mediated reversion (Fig. 1c) . In addition to the precise 8-bp deletion, we also observed that an additional approximately 17% of the alleles contained in-frame mutations, and therefore may encode hypomorphic alleles with some restoration of function (Extended Data  Fig. 1a, c) . Genotyping of 22 clones generated from a nuclease-treated LGMD2G iPS cell population revealed that 77% contained at least one wild-type allele, indicating that the majority of nuclease-treated cells would be therapeutically corrected (Fig. 1d, Supplementary Table 1 ). To independently verify the duplication collapse rates observed in edited iPS cells by Illumina short-read sequencing, we sequenced a 2-kb amplicon spanning the TCAP locus from a population of SpCas9-edited iPS cells using the Pacific Biosciences long-read sequencing platform Letter reSeArCH (PacBio) . Analysis of these reads revealed that 67% of the edited alleles with insertions or deletions below 100 bp in length corresponded to the 8-bp collapse, which is similar to the 73% rate of 8-bp collapse determined by Illumina sequencing for this sample (Extended Data  Fig. 2, Supplementary Table 2 ). Treatment of cells with Cas9 nuclease can produce large deletions (>100 bp) at the target locus at a modest frequency 10 . Consistent with these findings, our PacBio analysis revealed the presence of large deletions (100-1,000 bp) that would not have been detected by Illumina sequencing at a frequency of about 2% in bulk edited iPS cells. We also isolated a genotypically complex iPS cell colony that harboured two large deletions at the TCAP locus (Extended Data Fig. 3) .
To demonstrate the translatability of our approach to muscle cell types, we differentiated the LGMD2G iPS cells into proliferative skeletal myoblasts that can be induced to terminally differentiate into myotubes 11 . iPS cell-derived myoblasts can repair damaged muscle in a similar way to myogenic satellite cells (one of the primary targets of gene therapy for myopathies). Myoblasts were electroporated with SpCas9 RNPs programmed to target the 8-bp microduplication. Following editing, about 45% of the alleles were precisely repaired back to the wild-type sequence (Fig. 1e, Extended Data Fig. 1b, d ). Immunostaining of myotubes derived from corrected LGMD2G iPS cell clones with an anti-telethonin antibody showed that genetic correction restored telethonin expression (Extended Data Fig. 4) . Collectively, these data show that introducing a DSB close to the centre of microduplication can efficiently achieve precise in vitro correction of the 8-bp microduplication associated with LGMD2G in iPS cells and in myoblasts that mimic cell populations that would be therapeutically targeted in vivo.
We further tested our approach on a 16-bp pathogenic microduplication in exon 15 of HPS1, which is associated with HPS1 and leads to the production of a truncated protein responsible for this autosomal recessive disease 12 . HPS1 has a high prevalence in the Puerto Rican population, with a carrier rate of approximately 1 in 21 in the northwest region 2 . HPS proteins are involved in the biogenesis of lysosome-related organelle complexes (BLOCs), which are necessary for the proper trafficking of cargo to melanosomes, dense granules and lysosomes 13 .
Patients with HPS1 suffer from albinism, bleeding disorders, vision loss and progressive pulmonary fibrosis, which leads to premature death 14 .
We tested the efficiency of gene correction in a patient-derived B lymphocyte cell line (B-LCL) homozygous for the 16-bp microduplication by electroporating these cells with SpCas9 RNPs programmed to cleave two base pairs away from the centre of the microduplication (target site 1; Fig. 2a ). To accurately assess the observed editing rates, we added unique molecular identifiers (UMIs) to our PCR amplicons during Illumina library construction to allow the removal of any amplification bias 15 . We confirmed that this approach accurately captured the relative percentage of HPS1 microduplication and wild-type alleles present in a series of test populations (Extended Data Fig. 5 ). At HPS1 target site 1, we observed editing at about 46% of the alleles with around 35% restored to the wild-type sequence (Fig. 2b , c, Supplementary Table 2 ). We further examined the effect of the position of the DSB within the microduplication on the efficiency of MMEJ-mediated repair by designing five additional sgRNAs that targeted the DSB to different positions relative to the centre of the microduplication (target sites 2-6, Fig. 2a ). As the break site was shifted away from the centre, there was a decrease in the efficiency of achieving the precise 16-bp deletion (Fig. 2b, c) . However, target sites 3 and 6 were notable exceptions to this trend. Target site 3 proved to be quite efficient at generating indels to the exclusion of the 16-bp deletion (Extended Data Fig. 6 ), probably because the wild-type sequence, once regenerated, can also be targeted by this sgRNA for further mutagenesis. On the other hand, target site 6 achieved efficient deletion of the 16-bp microduplication (more than 50% of the modified alleles), despite being the most distal of the cleavage sites (10 bp from the centre of the microduplication). Its efficiency may be due to the extended regions of homology that surround the cleavage site at this end of the microduplication (target site 6; Fig. 2a) . Overall, these results demonstrate that the cleavage position within the microduplication and the presence of alternate regions of microhomology can influence the production of the desired wild-type end product (Fig. 2c) .
To investigate whether nuclease-mediated collapse of a microduplication occurs via the MMEJ pathway, we inhibited a DNA repair factor (PARP-1) that regulates DSB flux through this pathway. PARP-1 Letter reSeArCH influences the repair of a DSB through resection-dependent DNA repair pathways, such as MMEJ 3, 16 , which are in competition with the non-homologous end joining pathway (NHEJ) for DSB repair 17 (Extended Data Fig. 7a) . Inhibition of the catalytic activity of PARP-1 by rucaparib reduces DSB flux through the MMEJ pathway, resulting in a decrease in microhomology-based deletion products in the resulting repair events 18 (Extended Data Fig. 7a ). Patient-derived HPS1 B-LCL cells were treated with 10 μM or 20 μM rucaparib before and after treatment with SpCas9 RNP to suppress MMEJ-mediated repair of DSBs (Fig. 3a) . We observed an overall reduction in editing rates at the HPS1 locus upon rucaparib treatment (Fig. 3b) . These lower editing rates were primarily the result of a reduction in the 16-bp deletion product, which decreased from about 50% in untreated cells to around 15% and 6% in cells treated with 10 μM and 20 μM rucaparib, respectively ( Fig. 3b-d) . We observed a similar reduction in microhomology-based deletions with SpCas9 RNP targeting the AAVS1 locus in patient-derived HPS1 B-LCL cells (Extended Data Fig. 7) . Thus, the MMEJ pathway underlies the robust correction of the microduplications for LGMD2G and HPS1 in the presence of a targeted DSB.
To test the generality of this MMEJ-based repair approach and the range of sequence lengths over which duplication collapse is efficient, we evaluated the editing products generated by SpCas9 targeting endogenous microduplications within the human genome. We performed a bioinformatic analysis to identify non-pathogenic, unique endogenous microduplications ranging from 4 bp to 36 bp in length in the human genome (Fig. 4a) . We examined the efficiency of microduplication collapse resulting from a SpCas9 produced DSB at the centre of the microduplications in HEK293T cells at these sites. Although the bulk editing rate varied across these target sites, we consistently found that duplication collapse was the major end product within the edited alleles (ranging from 45% to 93%), regardless of the microduplication length (Fig. 4b, Extended Data Fig. 8a) . Consistent with the analysis at the HPS1 locus, we observed a decrease in the duplication collapse efficiency for 24-and 27-bp-long microduplications as cut sites were moved away from the centre (Extended Data Fig. 8b-g ).
Whereas SpCas9 generates blunt DSBs, the type V CRISPR-Cas nuclease Cas12a generates DSBs with 5′ overhangs 19 . We investigated whether LbCas12a-generated breaks might be preferentially repaired by a resection-dependent pathway such as MMEJ by comparing the efficiency of microduplication collapse engendered by SpCas9 and LbCas12a nucleases at three endogenous sites. Efficient repeat collapse (50-90% of edited alleles) could be achieved with LbCas12a at all three of these sites, with efficiencies similar to those of SpCas9 (Fig. 4c, Extended Data Fig. 8a ). Overall, these data demonstrate that Letter reSeArCH the MMEJ-based editing approach can be used to efficiently collapse microduplications up to lengths of at least 36 bp using either Cas9 or Cas12a programmable nucleases.
To investigate the potential of this MMEJ-based therapeutic strategy to be applied more broadly for correcting human genetic disorders, we performed a bioinformatic analysis to gauge the prevalence of disease-causing microduplications in human populations. The ClinVar database 20 includes about 4,700 duplications that are annotated as 'pathogenic' or 'pathogenic/likely pathogenic' (Extended Data Fig. 10a ). We focused on duplications of lengths ranging from 2 to 40 bp because our data indicate that microhomologies within this range can be precisely repaired via the MMEJ pathway (Fig. 4) . We also focused on 'simple' duplications-those for which the duplicated sequence is not part of a more complex repeat structure-to improve the odds that the primary homology-based collapse would result in the desired wildtype sequence. Finally, we examined all duplications in 'coding' regions (mainly exons plus 50 flanking bases) from the gnomAD exome and genome sequencing databases 21 to prioritize pathogenic duplications according to their frequencies in human populations (Extended Data Figs. 9, 10a). Our analysis yielded 143 likely disease-causing microduplications of lengths 2-40 bp that were observed at least once in gnomAD (Extended Data Fig. 10b ), some of which occur in specific subpopulations at substantial frequencies (for example, Tay-Sachs disease, Supplementary Table 3) .
To facilitate the utilization of our bioinformatics analysis, we have created an interactive, searchable webtool (https://rambutan. umassmed.edu/duplications/). This analysis also included the identification of potential Cas9 and Cas12a cleavage sites 22 within these microduplications (Supplementary Table 3 and expanded tables available at the website mentioned above). As shown by our guide 'tiling' data across the HPS1 microduplication and endogenous microduplication sites, the position of the DSB break within the duplication, and the use of a guide design that avoids cleavage of the wild-type allele, are critical for efficient, stable collapse of microduplications. Rapid advances are being made in characterizing nucleases with alternate specificities 23, 24 and in engineering nucleases with alternate or expanded recognition preferences [25] [26] [27] , which will make correction of disease-causing microduplications using the MMEJ-based approach even more effective.
DSBs at most genomic sites (for example, AAVS1, Extended Data Fig. 7 ) are repaired primarily through the NHEJ pathway, which can produce small insertions or deletions during imprecise repair 28 . Our data, which span DSBs in 12 sequences, indicate that microduplications are preferentially repaired via the MMEJ pathway, which yields predictable and efficient collapse. For this class of pathogenic mutations, precise repair via the MMEJ pathway provides a favourable alternative to homology-directed repair, which is inefficient in many cell types 29 . Consistent with our findings, MMEJ-mediated repair was recently used to efficiently correct the pathogenic microduplication associated with HPS1
30 . Although the use of allele frequencies from gnomAD can help to prioritize potential targets for MMEJ-based repair, this underestimates the extent of genetic diseases-particularly dominant ones-caused by microduplications (see Supplementary Discussion). As genomic and phenotypic data for the human population continue to accrue, we are likely to discover new pathogenic microduplications that can be corrected using this MMEJ-based approach. Although the molecular mechanisms and cell-type-specific efficiencies of the MMEJ pathway remain to be completely elucidated, our findings lay the foundation for pursuing MMEJ-based therapeutic approaches for LGMD2G, HPS1 and a broader spectrum of microduplication-based diseases.
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Human subjects. Cells for reprogramming TCAP iPS cell lines were recovered, with consent, from a skin biopsy from a patient with LGMD2G under a UMMS-IRB-approved protocol and assigned a de-identified ID number unlinked to the patient's medical record. The consent process included conditions for sharing de-identified samples and information with other investigators. No Protected Health Information will be shared at any time, per Health Insurance Portability and Accountability Act guidelines. Cell culture.
LGMD2G primary dermal fibroblasts were isolated from a skin biopsy from a patient with LGMD2G as described 31 . Fibroblasts were reprogrammed using the CytoTune 2.0 iPS Sendai Virus Reprogramming Kit (ThermoFisher Scientific) according to the manufacturer's directions. Clonal lines were expanded for 6-10 passages before banking. Immunostaining was performed to confirm the absence of Sendai virus and expression of OCT4. Human iPS cells were cultured in iPS-Brew XF medium (Miltenyi Biotec) and passaged every 3-5 days with Passaging Solution (Miltenyi Biotec) according to the manufacturer's directions.
Myoblasts were induced from iPS cells using a modification of the Genea Biocells protocol 11 . Following the generation of differentiated myotubes as described, cells were reseeded and cultured in human primary myoblast medium 32 . CD56 + cells were purified by FACS using an anti-CD56-APC antibody (BD Biosciences) or MACS (Miltenyi Biotec) according to the manufacturer's directions. Myogenicity was confirmed by immunostaining myoblast and myotube cultures using the mouse monoclonal antibodies MyoD clone 5.8 (DAKO) and MF20 (DSHB) (data not shown).
A lymphoblastoid cell line from B lymphocytes (B-LCL) derived from a patient with HPS1 who was homozygous for the 16-bp microduplication was purchased from Coriell (GM14606). The cell line was cultured following the recommended procedure using RPM1 1640 with 2 mM l-glutamine, 15% FBS and 1% penicillin/ streptomycin.
HEK293T cells were cultured following the recommended procedure using Dulbecco's modified Eagle's medium (DMEM), 10% FBS and 1% penicillin/streptomycin.
All cultures were maintained in a humidified incubator with 5% CO 2 at 37 °C. All cell lines were tested for mycoplasma contamination at regular intervals and the HEK293T cell line was authenticated by University of Arizona Genetics Core. Purification of SpCas9 and LbCas12a. Protein purification for 3×NLS-SpCas9 and LbCas12a-2×NLS followed a common protocol. The generation and characterization of the 3×NLS-SpCas9 (Addgene 114365) and LbCas12a-2×NLS (Addgene 114366) constructs have been described 46, 47 . The pET21a plasmid backbone (Novagen) is used to drive the expression of a hexa-His-tagged version of each protein. The plasmid expressing 3×NLS-SpCas9 (or LbCas12a-2×NLS) was transformed into Escherichia coli Rosetta (DE3)pLysS cells (EMD Millipore) for protein production. Cells were grown at 37 °C to an OD 600 of ~0.2, then shifted to 18 °C and induced at an OD 600 of ~0.4 for 16 h with isopropyl β-d-1-thiogalactopyranoside (IPTG, 1 mM final concentration). Following induction, cells were pelleted by centrifugation and then resuspended with Ni-NTA buffer (20 mM Tris pH 7.5, 1 M NaCl, 20 mM imidazole, 1 mM TCEP) supplemented with HALT Protease Inhibitor Cocktail, EDTA-Free (100×) (ThermoFisher Scientific) and lysed with M-110s Microfluidizer (Microfluidics) following the manufacturer's instructions. The protein was purified from the cell lysate using Ni-NTA resin, washed with five volumes of Ni-NTA buffer and then eluted with elution buffer (20 mM Tris, 500 mM NaCl, 500 mM imidazole, 10% glycerol, pH 7.5). The 3×NLS-SpCas9 (or LbCas12a protein) was dialysed overnight at 4 °C in 20 mM HEPES, 500 mM NaCl, 1 mM EDTA, 10% glycerol, pH 7.5. Subsequently, the protein was step dialysed from 500 mM NaCl to 200 mM NaCl (final dialysis buffer: 20 mM HEPES, 200 mM NaCl, 1 mM EDTA, 10% glycerol, pH 7.5). Next, the protein was purified by cation exchange chromatography (5 ml HiTrap-S column, buffer A: 20 mM HEPES pH 7.5, 1 mM TCEP; buffer B: 20 mM HEPES pH 7.5, 1 M NaCl, 1 mM TCEP; flow rate 5 ml/min, column volume 5 ml) followed by size-exclusion chromatography (SEC) on a Superdex-200 (16/60) column (isocratic size-exclusion running buffer: 20 mM HEPES pH 7.5, 150 mM NaCl, 1 mM TCEP for 3×NLS-SpCas9 or 20 mM HEPES pH 7.5, 300 mM NaCl, 1 mM TCEP for LbCpf1-2×NLS). The primary protein peak from the SEC was concentrated in an Ultra-15 Centrifugal Filters Ultracel-30K (Amicon) to a concentration around 100 μM based on absorbance at 280 nm. The purified protein quality was assessed by SDS-PAGE/Coomassie staining to be >95% pure and protein concentration was quantified with a Pierce BCA Protein Assay Kit (ThermoFisher Scientific). Protein was stored at −80 °C until further use. In vitro transcription of guide RNAs. The DNA cassette containing the U6 promoter and the sgRNA framework for SpCas9 was cloned from pLKO1-puro vector 33 into pBluescript SK II+ backbone 47 . Plasmids expressing each guide RNA from the U6 promoter were constructed by annealing oligonucleotides encoding guide RNA and cloning it into BfuAI cleavage sites in this vector (Supplementary  Table 4 ). Templates for in vitro transcription of SpCas9 guides were amplified from the cognate plasmids using NEB Q5 High-Fidelity DNA Polymerase for 30 cycles (98 °C, 15 s; 65 °C, 25 s; 72 °C, 20 s) using primer sets designed to include the T7 scaffold (Supplementary Table 5 ). To generate CRISPR RNA (crRNA) for LbCas12a, templates for in vitro transcription were generated by PCR amplification of oligonucleotides designed to include the T7 scaffold along with the guide RNA and a 15-mer overlap sequence to allow annealing between the oligos (Supplementary Table 8 ). The oligonucleotides encoded the full-length direct repeat crRNA sequence 47 . Thirty cycles of amplification were conducted using NEB Q5 High-Fidelity DNA polymerase (98 °C, 15 s; 60 °C, 25 s; 72 °C, 20 s). The PCR products were purified using Zymo DNA Clean & Concentrator Kit (Zymo D4005). In vitro transcription reactions were performed using the HiScribe T7 High Yield RNA Synthesis Kit using 300 ng of PCR product as template (NEB E2040S). After incubation for 16 h at 37 °C, samples were treated with DNase I for 40 min at 37 °C to remove any DNA contamination. Each guide RNA was purified using the Zymo RNA Clean and Concentrator Kit. Final RNA concentration was measured using Nanodrop and RNA was stored at −80 °C until further use. Electroporation of cell lines with SpCas9 RNPs. 3×NLS-SpCas9 protein was precomplexed with sgRNAs either purchased from Synthego or made in-house by T7 transcription (Supplementary Table 6 ) and electroporated into cells using the Neon transfection system (ThermoFisher Scientific). ) were resuspended in 10 μl RNP-Buffer R mix and then nucleofected as follows: pulse voltage 1,500 V, pulse width 20 ms, pulse number 1. After transfection, the cells were plated onto Matrigel-coated 24-well plates with iPS Brew XF supplemented with 10 μM Y27632 for expansion and grown in a humidified incubator at 37 °C, 5% CO 2 , for 4 days before collecting them for analysis. iPS cell-derived myoblasts were electroporated using two pulses of 1,400 V and 20 ms width and plated onto a 24-well dish containing pre-warmed antibiotic-free human primary myoblast growth medium and cultured for 4-6 days before analysis.
Electroporation of HPS1 patient-derived B-LCL cells. In brief, 40 pmol of 3×NLS-
SpCas9 protein was precomplexed with 50 pmol of sgRNA in buffer R for 10-20 min at room temperature in a final volume of 12 μl. Then, 300,000 cells per reaction were resuspended in 10 μl of RNP-buffer R mix and electroporated with 2 pulses at 1,700 V for 20 ms using the 10-μl tip. Cells were then plated in 24-well plates with 500 μl of pre-equilibrated antibiotic-free culture medium and grown in a humidified incubator at 37 °C and 5% CO 2 for 7 days before indel analysis.
For the PARP-1 inhibition experiments, 300,000 HPS1 patient-derived B-LCL cells were treated with 10 μM or 20 μM rucaparib camsylate (Sigma-Aldrich PZ0036) in standard growth medium for 24 h. Treated cells were electroporated with SpCas9 RNPs as described above. Following another 24 h incubation in rucaparib-containing medium, cells were resuspended in PARP-1 inhibitor-free medium and collected for analysis after 7 days. Electroporation of HEK293T cells. In brief, 20 pmol of 3×NLS-SpCas9 protein and 25 pmol of in vitro transcribed sgRNA were pre-complexed in buffer R for 10-20 min at room temperature. Then, 100,000 cells per reaction were resuspended in 10 μl of RNP-buffer R mix and nucleofected with SpCas9 guide RNA complex using two pulses at 1,150 V for 20 ms using the 10-μl tip. Cells were then plated in 24-well plates with 500 μl of pre-equilibrated antibiotic-free culture medium and grown for 3 days before analysis. For Cas12a editing experiments at endogenous microduplications, 80 pmol of LbCas12a protein was pre-complexed with 100 pmol of in vitro transcribed crRNA and 100,000 cells per reaction were nucleofected as described above. Indel analysis by TIDE. Genomic DNA was extracted from HEK293T cells using GenElute Mammalian Genomic DNA Miniprep Kit (Sigma Aldrich) according to the manufacturer's instructions. The DNA region containing the 24-bp microduplication was amplified using genomic DNA as template and primers listed in Supplementary Table 7 using NEB Q5 High-Fidelity DNA Polymerase (98 °C, 15 s; 67 °C, 25 s; 72 °C, 20 s) for 30 cycles. Subsequently, the PCR product was purified using the DNA Clean & Concentrator-5 kit (Zymo) and sequenced. Sanger sequencing trace data were analysed using the TIDE webtool at https://tide.nki.nl/ to infer the compositions of indels created at the sites of DSBs 34 . Library construction for Illumina deep sequencing. Library construction for deep sequencing was performed using a modified version of our previously described protocol 26 . In brief, iPS cells and myoblasts were collected following nuclease treatment and genomic DNA was extracted using the GenElute Mammalian Genomic DNA Miniprep Kit (Sigma-Aldrich G1N350). Genomic loci spanning the target sites were PCR amplified with locus-specific primers carrying tails complementary to the TruSeq adapters (Deepseq_TCAP_primer_fwd and Deepseq_TCAP_primer_rev; Supplementary Table 8) . Subsequently, 50 ng of input genomic DNA was PCR amplified with Q5 High-Fidelity DNA Polymerase
μl of each PCR reaction was amplified with barcoded primers to reconstitute the TruSeq adaptors using Q5 High-Fidelity DNA Polymerase (New England Biolabs): (98 °C, 15 s; 67 °C, 25 s; 72 °C, 20 s) for 10 cycles. Products were qualitatively analysed by gel electrophoresis. Equal amounts of the products were pooled and gel-purified using QIAquick Gel Extraction Kit (Qiagen 28704). The purified library was deep sequenced using a paired-end 150-bp Illumina MiSeq run. Illumina deep sequencing analysis. MiSeq data analysis was performed using Unix-based software tools. First, we used FastQC (version 0.11.3; http://www.bioinformatics.babraham.ac.uk/projects/fastqc/) to determine the quality of pairedend sequencing reads (R1 and R2 fastq files). Next, we used paired-end read merger (PEAR; version 0.9.8) 35 to pool raw paired-end reads and generate single merged high-quality full-length reads. Reads were then filtered according to quality via FASTQC 36 for a mean PHRED quality score above 30 and a minimum per base score above 24. After that, we used BWA (version 0.7.5) and SAMtools (version 0.1.19) to align each group of filtered reads to a corresponding reference sequence. To determine lesion type, frequency, size and distribution, all edited reads from each experimental replicate were combined and aligned, as described above. Lesion types and frequencies were then catalogued in a text output format at each base using bam-readcount. For each treatment group, the average background lesion frequencies (based on lesion type, position and frequency) of the triplicate negative control group were subtracted to obtain the nuclease-dependent lesion frequencies. Library construction for UMI-based Illumina deep sequencing. The construction of the UMI-based library used a linear amplification step to incorporate UMIs within the amplicons from the target locus 15 . HPS1 B-LCL cells and HEK293T cells were collected following nuclease treatment for genomic DNA extraction using the GenElute Mammalian Genomic DNA Miniprep Kit (Sigma G1N350). Randomized unique molecular identifiers (UMIs) were incorporated within the 5′ locusspecific primers carrying tails complementary to TruSeq adaptors (Supplementary Table 8 ). In brief, 50 ng of input genomic DNA was linear amplified with NEB Q5 High-Fidelity DNA Polymerase (98 °C, 15 s; 67 °C, 25 s; 72 °C, 20 s) for 10 cycles using the 5′ locus-specific primer with TruSeq adaptor conjugated with a UMI sequence. Next a 5′ constant primer along with the 3′ locus-specific primer with TruSeq adaptor were added and further amplified for 30 cycles. Indexes were then incorporated using barcoded primers to diluted PCR products using NEB Q5 High-Fidelity DNA Polymerase (98 °C, 15 s; 67 °C, 25 s; 72 °C, 20 s) for 10 cycles. Products were qualitatively analysed by gel electrophoresis. Equal amounts of the products were pooled and gel-purified using QIAquick Gel Extraction Kit (Qiagen 28704) for DNA recovery. The purified library was deep sequenced using a pairedend 150-bp Illumina MiSeq run. UMI-based deep sequencing analysis. We adapted the analysis of the UMI-tagged deep sequencing reads from our previous protocol 15 . Initially, BWA (version 0.7.5) and SAMtools (version 0.1.19) were used to align each group of filtered mergedread pairs to a corresponding reference sequence, ignoring the unique molecular barcodes. Next, we used a custom Python and PySAM script to process mapped reads into counts of UMI-labelled reads for each target. The mapped reads were filtered by requiring a mapping value (MAPQ) larger than 30. Alignments were categorized into different categories of indels using VarScan 2 37 . Next, we identified UMI duplicates and the minimal set of amplicons that can account for the full set of reads with unique UMIs. For each unique UMI, a minimum of five observations of the same sequence was required to consider the sequence to have a low likelihood of being an artefact (sequencing error in the UMI element). For sequences that met this threshold, all common sequences associated with the UMI were consolidated to one read for analysis of the distribution of sequence modifications that were present at a locus. The resulting UMI number tables, which describe the type of each sequence modification and its length, were concatenated and loaded into GraphPad Prism 7 for data visualization. Microsoft Excel version 16.21.1 was used for statistical analysis. PacBio library preparation. Single molecule, real-time (SMRT) sequencing is modified from Pacific Biosciences (PacBio). Nuclease-treated patient-derived iPS cells were collected for genomic DNA extraction with GenElute Mammalian Genomic DNA Miniprep Kit (Sigma G1N350). In brief, regions that flanked the TCAP target site were PCR amplified using locus-specific primers (Supplementary Table 8 ). The forward primer was designed to have the barcode sequence followed by the UMI and locus-specific primer sequence. The reverse primer contains the barcode followed by the locus-specific primer sequence. Input DNA (25-50 ng) was PCR amplified with Phusion High Fidelity DNA Polymerase (New England Biolabs): (98 °C, 15 s; 65 °C, 25 s; 72 °C, 18 s) for 30 cycles. The products were qualitatively analysed by gel electrophoresis and subsequently gel purified with QIAquick Gel Extraction Kit (Qiagen 28704). The purified products were sent to the UMASS Medical School Deep Sequencing Core for SMRTbell Library Preparation and sequencing on the Pacific Biosciences Sequel Instrument. PacBio sequencing data analysis. For PacBio sequencing data analysis, Minimap2 (version 2.14 38 ) was used to align the raw Consensus_ROI (reads_of_insert.fastq) data to the 2-kb reference sequence. Alignment quality control and filtering were performed using custom Perl script to remove errors and filter out alignments with poor quality. For variation calling, a custom Python script was used to extract deletions or insertions larger than 5 bp for each read from the SAM files. Subsequently, deletions or insertions were classified into different groups on the basis of their length. IGV(version 2.4.16) was used for alignment visualization of the aligned reads using Quick consensus mode 39 .
Clonal analysis of iPS cells.
Following confirmation of MMEJ-mediated correction in the population of LGMD2G iPS cells, clonal analysis was performed. Cells from the corrected population were seeded into 96-well plates in the presence of Y27632 at a frequency of 0.8 cells per well. iPS cell clones were cultured for several weeks in iPS Brew XF (Miltenyi Biotec) before being collected for sequence analysis by deep-sequencing. Myoblast differentiation and detection of telethonin expression. iPS cell-derived myoblasts were plated into 0.1% gelatin-coated 6-well plates at a density of 100,000 cells per well in myoblast expansion medium containing Ham's F10 (Cellgro) supplemented with 20% FBS (Hyclone, SH30071.03), 1.2 mM CaCl 2 (EMD OmniPur 3000) and 1% chick embryo extract isolated from day 12 SPF Premium Fertilized White Leghorn Chicken Eggs (Charles River). After 4 days of expansion, the cells were incubated with myotube differentiation medium including DMEM/F12 (ThermoFisher Scientific) supplemented with 1% N2 (ThermoFisher Scientific, 17502-048) and 1% insulin-transferrin-selenium (ThermoFisher Scientific, 41400045). After 10 days of differentiation, the cells were dissociated into single cells using TrypLE. Subsequently the cells were fixed with 2% PFA for 15 min and blocked with PBS including 2% BSA, 2% horse serum, 2% goat serum and 2% Triton X-100 for 20 min. The cells were then incubated with anti-telethonin antibody (Santa Cruz, sc-25327, 1:50) at 4 °C for 2 days and IgG goat anti-mouse secondary antibody labelled with Alexa 488 fluorophore (Invitrogen, A11017, 1:800) at room temperature for 1 h. The cells were suspended in flow buffer (PBS including 0.2% FBS) and flow cytometry was performed using a BD FACSAria IIu (UMMS Flow Cytometry Core Laboratory). Roughly 20,000 cells were included for analysis. FlowJo software (version 7.6) was used for data analysis. Survey of microduplications in ClinVar and in human reference populations. Annotations of pathogenicity from ClinVar (ftp://ftp.ncbi.nlm.nih.gov/ pub/clinvar/vcf_GRCh37/archive_2.0/2018/clinvar_20180128.vcf.gz) 20 were combined with annotations of allele-frequencies from gnomAD (https://console.cloud.google.com/storage/browser/gnomad-public/release/2.0.2/vcf) 21 and from the 1000 Genome Project (ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/ release/20130502/) 40 using the annotate function in bcftools 41 (1.9), after decomposition of multi-allelic sites and normalization of variants with vt 42 (v0.5772) against the reference genome http://www.broadinstitute.org/ftp/pub/seq/references/Homo_sapiens_assembly19.fasta. Most analyses were restricted to the intervals in ftp://ftp.broadinstitute.org/pub/ExAC_release/release1/resources/ exome_calling_regions.v1.interval_list. Insertions were extracted using vt (view -h -f "VTYPE==INDEL&&DLEN>0"); then duplications were identified, repeat units counted, internal shift-symmetries determined, and flanking genomic regions extracted using a modified version of the vt function annotate_indels. Additional processing (filtering, finding maximal allele frequencies among different populations, scanning for PAM sites and so on) was performed using R (3.4.3), including the VariantAnnotation (1.24.5) package 43 . Exact tandem repeats in the reference genome were identified using the Tandem Repeats Finder program (4.09) 44 and checked for exact matches elsewhere in the genome with bwa fastmap (0.7.17) 45 . Examples of different lengths were manually selected to use for the tests of collapse of endogenous microduplications. Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this paper.
Data availability
Raw data associated with Extended Data Fig. 10 are reported in Supplementary  Table 3 . Raw script used for retrieving microduplication data listed in Supplementary Table 3 will be available upon request. Raw Illumina sequencing reads and PacBio data for this study have been deposited in the National Center for Biotechnology Information Short Read Archive under bioproject ID PRJNA517630.
Code availability
Data analysis used a combination of publicly available software and custom code, as detailed in the Methods. Custom Python (CRESA-lpp.py) and R (indel_back-ground_filtering.R) scripts used in the Illumina data analysis and the shell script (Tcap_pacbio_analysis.sh) used for the analysis of the PacBio data are hosted on GitHub (https://github.com/locusliu/PCR_Amplicon_target_deep_seq). Scripts for the bioinformatic analysis of pathogenic microduplications are hosted at https:// rambutan.umassmed.edu/duplications/. Table 9 ). ***P = 0.0004, ****P = 6.5 × 10 The PAM sequence is outlined in magenta and the protospacer sequence is underlined. Magenta carets indicate the site of DSB. c, Percentage of alleles with 24-bp deletion (green) and total indels (blue) for all three guides from TIDE analysis. Guide 3 produces primarily 23-bp deletions, but not 24-bp deletions, probably because it recuts the collapsed DNA sequence. Bars shows the mean from n = 3 biological repeats, individual data points are represented by dots. d, Proportion of the 24-bp deletion out of total indels as individual data points (dots), with mean ± s.e.m. n = 3 biological repeats. e, Schematic of endogenous site containing a 27-bp microduplication for SpCas9 target sites 1 and 2. f, Percentage of alleles with 27-bp deletion (green) and total indels (blue) for both guides from UMI-based Illumina deep sequencing. Bars show the mean from n = 3 biological repeats, individual data points are represented by dots. g, Proportion of the 27-bp deletion out of total indels as individual data points (dots) with mean ± s.e.m. n = 3 biological replicates. Fig. 9 | Bioinformatics pipeline for identification of disease alleles. Schematic shows the bioinformatics pipeline used to identify all microduplications amendable to efficient MMEJ-mediated collapse from the 'coding' regions (exome_calling_regions.v1; mainly exons plus 50 flanking bases) in the gnomAD genome and exome databases (version 2.0.2). Insertion variants observed in both databases were used for analysis (variants occurring in both databases were counted once). Insertions that do not add a repeat unit to an existing tandem repeat and are not themselves a perfect repeat were filtered to constrain only duplications that spanned 2-40 bp in length and are amendable to CRISPR-Cas9 targeting. This dataset was then cross-referenced against the ClinVar database (clinvar_20180225.vcf) to apply further filters for variants reported as pathogenic, which ultimately yielded 143 likely disease-causing microduplications. The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
Letter reSeArCH
Extended Data
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Field-specific reporting Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences
Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
Three biological replicates were used in all the experiments. This number of replicates is necessary to calculate significance of each data point (standard deviation). No other statistical methods were used to determine sample size.
Data exclusions No data point was excluded
Replication Biological replicates confirm the reproducibility of our experimental findings and standard errors were within range of experimental error.
Randomization No randomization was used as the data presented does not require randomization.
Blinding
The data presented does not require the use of blinding.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response. 
Validation
The antibody was validated using western blots on human tissue expressing telethonin and in cell culture overexpressing epitope-tagged telethonin from a plasmid. The data is included in extended figure 4.
Eukaryotic cell lines Policy information about cell lines
Cell line source(s) HPS1 B-LCL was obtained from Coriell institute, iPSC and myoblasts were derived from primary LGMD2G primary dermal fibroblasts isolated from the skin biopsy of human subject RB25199. Human Embryonic Kidney (HEK293T) cell line was a gift from our collaborator M. Green (at UMass Medical School, Worcester, Massachusetts, USA)
Authentication
Yes. HEK293T cells authenticated by University of Arizona Genetics Core.
Mycoplasma contamination HEK293T cells were tested for mycoplasma contamination at regular intervals
Commonly misidentified lines (See ICLAC register)
None of the cell lines used in this study is categorized as a commonly misindentified cell line.
